Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kathleen Irena Junusmin"'
Autor:
Caroline Mahendra, Maria Mardalena Martini Kaisar, Suraj Rajan Vasandani, Sem Samuel Surja, Enty Tjoa, Febie Chriestya, Kathleen Irena Junusmin, Tria Asri Widowati, Astrid Irwanto, Soegianto Ali
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 11 (2021)
Saliva as a sample matrix has been an attractive alternative for the detection of SARS-CoV-2. However, due to potential variability in collection and processing steps, evaluating a proposed workflow amongst the local population is recommended. Here,
Externí odkaz:
https://doaj.org/article/38c1211313e24363947781a21563cfd0
Autor:
Fadhli Adesta, Caroline Mahendra, Kathleen Irena Junusmin, Arya Melissa Selva Rajah, Sharon Goh, Levana Sani, Alexandre Chan, Astrid Irwanto
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Administration of pharmacogenomics (PGx) testing in clinical practice has been suboptimal, presumably due to lack of PGx education. Here, we aim to evaluate the standpoint of PGx testing among a diverse group of healthcare professionals (
Externí odkaz:
https://doaj.org/article/ea2ae33596334edc9e356db8550354a8
Autor:
Baitha Palanggatan Maggadani, Kathleen Irena Junusmin, Levana L. Sani, Caroline Mahendra, Margareta Amelia, Gabriella Gabriella, Astrid Irwanto, Alexandre Chan, Harmita Harmita, Yahdiana Harahap, Samuel J. Haryono
PurposeTamoxifen, common adjuvant therapy prescribed in estrogen receptor positive (ER+) breast cancer, is metabolized by CYP2D6 enzyme into endoxifen. The phenotypes of CYP2D6, a highly polymorphic gene, vary from ultrarapid (UM), normal (NM), inter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa5d46ed53f7877b872cca992941885a
https://doi.org/10.21203/rs.3.rs-1037721/v1
https://doi.org/10.21203/rs.3.rs-1037721/v1
Autor:
Kathleen Irena Junusmin, Baitha Palanggatan Maggadani, Amelia M, Astrid Irwanto, Levana Sani, Yahdiana Harahap, Caroline Mahendra, Samuel J. Haryono, Gabriella, Harmita
Tamoxifen is a Selective Estrogen-Receptor Modulator (SERM) commonly prescribed for standard of care in estrogen receptor positive (ER+) breast cancer as an adjuvant therapy. Tamoxifen is metabolized by CYP2D6 into its active metabolite, endoxifen, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a3d320ddca406c0d93183178d87244b
https://doi.org/10.1101/2021.06.25.21259564
https://doi.org/10.1101/2021.06.25.21259564